Long Term Ventilation
Conditions
Brief summary
The purpose of this study is to determine whether Inhalation of Recombinant Human Deoxyribonuclease Shortens Ventilation Time in Mechanically Ventilated Adults
Detailed description
Recombinant human deoxyribonuclease I (rhDNase, dornase alpha), administered by inhalation, is currently used as a mucolytic agent in the treatment of cystic fibrosis. This prospective, randomized, placebo-controlled, double-blind clinical study should carry out whether the therapeutic use of rhDNase can be extended to adults who are undergoing long term ventilation at the intensive care. It is hypothesized that mechanically ventilated patients show elevated concentrations of DNA in airway secretions, and that these pathological DNA levels are reduced by rhDNase. The primary clinical goal of the study is to establish wether ventilation times are shortend under inhalation of rhDNAse during the ventilation time. hDNase (verum) is compared with equal amounts of 0.9% saline solution (placebo).
Interventions
DRUGdornase alfa
Sponsors
Joachim Riethmueller, Dr. med.
University Hospital Tuebingen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* adult * mechanical ventilation * expected ventilation time 3 days or longer * full therapy is possible * expectet ventilation time not longer than 21 days
Exclusion criteria
* medicinal point of view: patient won´t survive the next 21 days * concomitant pneumococcal disease (like tuberculosis, carcinoma) * endotracheal bleeding * pneumothorax with no relief (e.g. thoracic drainage) * pregnancy * breast feeding * participation in another clinical trail * mechanical ventilation since more than 48 hours * mechanical ventilation on the basis of another reason than operation, trauma or pulmonary decompensation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time of mechanical ventilation from beginning of the ventilation-therapy up to the end of the ventilation-therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| improval of pulmonaryfunction | — |
| reduction of pneumonia | — |
| reduction of atelectasis / dystelectasis | — |
| length of stay at the Intensive Care Unit | — |
| length of stay at the hospital | — |
| reduction of DNA concentrations in Airway Secretions | — |
Countries
Germany
Outcome results
None listed